NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
85.90
+0.61 (+0.72%)
At close: 4:02PM EDT

85.64 -0.26 (-0.30%)
Pre-Market: 7:54AM EDT

Stock chart is not supported by your current browser
Previous Close85.29
Open86.07
Bid85.60 x 2900
Ask85.64 x 3000
Day's Range85.79 - 86.32
52 Week Range72.30 - 94.19
Volume1,342,691
Avg. Volume1,813,889
Market Cap197.868B
Beta0.91
PE Ratio (TTM)14.60
EPS (TTM)5.88
Earnings DateN/A
Forward Dividend & Yield2.98 (3.47%)
Ex-Dividend Date2018-03-06
1y Target Est98.50
Trade prices are not sourced from all markets
  • The Wall Street Journal9 hours ago

    [$$] Novartis to Cut 2,000 Jobs Amid Revamp

    Novartis AG plans to cut more than 2,000 jobs as part of a global restructuring, the latest move by its new chief executive to refocus the pharmaceutical giant on higher-value drugs. The Swiss company said Tuesday that most of the cuts would fall in its home market, where it plans to eliminate a net 1,000 production jobs—after taking into account the creation of 450 positions—and 700 positions in business services. Novartis said the layoffs will take place through 2022.

  • Novartis Layoffs 2018: NVS to Cut 2,000 + Jobs
    InvestorPlace15 hours ago

    Novartis Layoffs 2018: NVS to Cut 2,000 + Jobs

    The pharmaceutical giant said that the CEO ordered the move as the Swiss company hopes to turn its focus towards manufacturing and distributing higher-value drugs. All in all, Novartis will eliminate a net of 1,000 production jobs as the pharma company will also add 450 new positions in its home market, as well as 700 positions in its business services. The pharmaceutical giant currently has 12,800 employees, which means that it will lose more than 7% of its workforce if it gets rid of more than 2,000 jobs and adds about 1,150 new ones.

  • Tencent Going for China’s $2.3 Trillion Healthcare Market
    Market Realist19 hours ago

    Tencent Going for China’s $2.3 Trillion Healthcare Market

    China’s healthcare market was estimated to be ~$710 billion in 2017, and it’s on track to hit $2.3 trillion by 2030, according to government estimates cited by the People’s Daily newspaper. Tencent (TCEHY) is pursuing this opportunity. In recent months, Tencent has partnered with several global drugmakers to help it capitalize on China’s rapidly expanding healthcare market.

  • Analysts See a Strong Upside in Novavax Stock
    Market Realist23 hours ago

    Analysts See a Strong Upside in Novavax Stock

    In September 2018, of the total eight analysts covering Novavax (NVAX), five analysts have given Novavax stock a “buy” or higher rating, and three analysts have given Novavax a “hold” rating. The mean rating for Novavax stock is 2.13 with a target price of $3.86, implying an upside potential of 141.3% over Novavax’s closing price of $1.60 as of September 21.

  • Associated Pressyesterday

    Novartis plans to cut 2,100 jobs in Switzerland, Britain

    GENEVA (AP) — Novartis said Tuesday it's cutting some 2,100 jobs in Switzerland and Britain over several years as the Swiss pharmaceuticals giant tweaks its corporate structure to become more nimble and more efficient.

  • Reutersyesterday

    Novartis to cut 2,550 jobs in Switzerland, UK in profit push

    Novartis will cut 2,550 jobs in Switzerland and Britain over four years, it said on Tuesday, as the Swiss drugmaker strives to boost profits and focus on new medicines. Switzerland will bear the brunt, with 2,150 cuts planned at four factories and its Swiss-based business services unit. Novartis currently employs around 124,000 people worldwide.

  • The Wall Street Journalyesterday

    [$$] European Corporate Roundup

    Sweeping job cuts by pharmaceutical giant Novartis and an upbeat trading statement by retailer Next are the corporate highlights in Europe Tuesday.

  • The Wall Street Journalyesterday

    [$$] Novartis Cuts Over 2,000 Jobs in Switzerland

    AG (NOVN.EB) said Tuesday that it plans to cut more than 2,000 jobs in Switzerland, the latest move by a large Swiss pharmaceuticals company to optimize its operations. Earlier this month, the company said it would sell part of its generics business in the U.S. for up to $1 billion.

  • What Investors Should Know About Novartis AG’s (VTX:NOVN) Financial Strength
    Simply Wall St.yesterday

    What Investors Should Know About Novartis AG’s (VTX:NOVN) Financial Strength

    There are a number of reasons that attract investors towards large-cap companies such as Novartis AG (VTX:NOVN), with a market cap of CHF190.10b. Doing business globally, large caps tend toRead More...

  • Financial Timesyesterday

    [$$] Novartis slashes jobs in UK and Switzerland

    is planning 1,700 job cuts in Switzerland as well as up to 400 job losses in the UK and the end of manufacturing in Grimsby, as part of a global programme to slash production costs and boost profitability. Vas Narasimhan, chief executive since February, said the cuts were the result of the Swiss company’s strategic move away from high-volume drug production towards more specialised and personalised medicines. The reductions were part of a programme announced in 2016 to achieve $1bn in annual manufacturing cost savings in its production network by 2020.

  • Novartis to cut 2,550 jobs in Switzerland, UK in profit push
    Reutersyesterday

    Novartis to cut 2,550 jobs in Switzerland, UK in profit push

    Novartis will cut 2,550 jobs in Switzerland and Britain over four years, it said on Tuesday, as the Swiss drugmaker strives to boost profits and focus on new medicines. Switzerland will bear the brunt, with 2,150 cuts planned at four factories and its Swiss-based business services unit. Novartis currently employs around 124,000 people worldwide.

  • Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
    Zacks2 days ago

    Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar

    Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.

  • Ann Taylor's parent company reports major beat, Google CEO heads to Washington, Boeing pulls major upset
    Yahoo Finance Video21 hours ago

    Ann Taylor's parent company reports major beat, Google CEO heads to Washington, Boeing pulls major upset

    Ascena, Google, Boeing, Novartis and Walmart are the companies to watch.